View in EDS HTML Full Text PDF Full Text

CDK2 inhibition enhances CDK4/6 inhibitor antitumor activity in comprehensive breast cancer PDX model screen.

Saved in:
Bibliographic Details
Title: CDK2 inhibition enhances CDK4/6 inhibitor antitumor activity in comprehensive breast cancer PDX model screen.
Authors: House NC; Blueprint Medicines Corporation, Cambridge, MA, USA. NHouse@blueprintmedicines.com., Chen MM; Blueprint Medicines Corporation, Cambridge, MA, USA., Khazaei S; TRACTION - Translational Research to AdvanCe Therapeutics and Innovation in ONcology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Brown V; Blueprint Medicines Corporation, Cambridge, MA, USA., Ramsden P; Blueprint Medicines Corporation, Cambridge, MA, USA., Peng DH; TRACTION - Translational Research to AdvanCe Therapeutics and Innovation in ONcology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Moore S; Blueprint Medicines Corporation, Cambridge, MA, USA., Yuan L; Blueprint Medicines Corporation, Cambridge, MA, USA., Wu R; Blueprint Medicines Corporation, Cambridge, MA, USA., Wang F; TRACTION - Translational Research to AdvanCe Therapeutics and Innovation in ONcology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Luo L; Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Feng N; TRACTION - Translational Research to AdvanCe Therapeutics and Innovation in ONcology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Bristow CA; TRACTION - Translational Research to AdvanCe Therapeutics and Innovation in ONcology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Yap TA; Department of Investigational Cancer Therapeutics, Therapeutic Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Keyomarsi K; Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Marszalek JR; TRACTION - Translational Research to AdvanCe Therapeutics and Innovation in ONcology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ribich S; Blueprint Medicines Corporation, Cambridge, MA, USA., Rinne ML; Blueprint Medicines Corporation, Cambridge, MA, USA., Muthuswamy LB; Blueprint Medicines Corporation, Cambridge, MA, USA., Faia KL; Blueprint Medicines Corporation, Cambridge, MA, USA.
Source: NPJ breast cancer [NPJ Breast Cancer] 2025 Dec 03; Vol. 11 (1), pp. 135. Date of Electronic Publication: 2025 Dec 03.
Publication Type: Journal Article
Journal Info: Publisher: Breast Cancer Research Foundation Country of Publication: United States NLM ID: 101674891 Publication Model: Electronic Cited Medium: Print ISSN: 2374-4677 (Print) Linking ISSN: 23744677 NLM ISO Abbreviation: NPJ Breast Cancer Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41339342
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: CDK2 inhibition enhances CDK4/6 inhibitor antitumor activity in comprehensive breast cancer PDX model screen.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22House+NC%22">House NC</searchLink>; Blueprint Medicines Corporation, Cambridge, MA, USA. NHouse@blueprintmedicines.com.<br /><searchLink fieldCode="AU" term="%22Chen+MM%22">Chen MM</searchLink>; Blueprint Medicines Corporation, Cambridge, MA, USA.<br /><searchLink fieldCode="AU" term="%22Khazaei+S%22">Khazaei S</searchLink>; TRACTION - Translational Research to AdvanCe Therapeutics and Innovation in ONcology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Brown+V%22">Brown V</searchLink>; Blueprint Medicines Corporation, Cambridge, MA, USA.<br /><searchLink fieldCode="AU" term="%22Ramsden+P%22">Ramsden P</searchLink>; Blueprint Medicines Corporation, Cambridge, MA, USA.<br /><searchLink fieldCode="AU" term="%22Peng+DH%22">Peng DH</searchLink>; TRACTION - Translational Research to AdvanCe Therapeutics and Innovation in ONcology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Moore+S%22">Moore S</searchLink>; Blueprint Medicines Corporation, Cambridge, MA, USA.<br /><searchLink fieldCode="AU" term="%22Yuan+L%22">Yuan L</searchLink>; Blueprint Medicines Corporation, Cambridge, MA, USA.<br /><searchLink fieldCode="AU" term="%22Wu+R%22">Wu R</searchLink>; Blueprint Medicines Corporation, Cambridge, MA, USA.<br /><searchLink fieldCode="AU" term="%22Wang+F%22">Wang F</searchLink>; TRACTION - Translational Research to AdvanCe Therapeutics and Innovation in ONcology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Luo+L%22">Luo L</searchLink>; Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Feng+N%22">Feng N</searchLink>; TRACTION - Translational Research to AdvanCe Therapeutics and Innovation in ONcology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Bristow+CA%22">Bristow CA</searchLink>; TRACTION - Translational Research to AdvanCe Therapeutics and Innovation in ONcology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Yap+TA%22">Yap TA</searchLink>; Department of Investigational Cancer Therapeutics, Therapeutic Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Keyomarsi+K%22">Keyomarsi K</searchLink>; Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Marszalek+JR%22">Marszalek JR</searchLink>; TRACTION - Translational Research to AdvanCe Therapeutics and Innovation in ONcology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Ribich+S%22">Ribich S</searchLink>; Blueprint Medicines Corporation, Cambridge, MA, USA.<br /><searchLink fieldCode="AU" term="%22Rinne+ML%22">Rinne ML</searchLink>; Blueprint Medicines Corporation, Cambridge, MA, USA.<br /><searchLink fieldCode="AU" term="%22Muthuswamy+LB%22">Muthuswamy LB</searchLink>; Blueprint Medicines Corporation, Cambridge, MA, USA.<br /><searchLink fieldCode="AU" term="%22Faia+KL%22">Faia KL</searchLink>; Blueprint Medicines Corporation, Cambridge, MA, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101674891%22">NPJ breast cancer</searchLink> [NPJ Breast Cancer] 2025 Dec 03; Vol. 11 (1), pp. 135. <i>Date of Electronic Publication: </i>2025 Dec 03.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Breast+Cancer+Research+Foundation%22">Breast Cancer Research Foundation </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101674891 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Print <i>ISSN: </i>2374-4677 (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2223744677%22">23744677 </searchLink><i>NLM ISO Abbreviation: </i>NPJ Breast Cancer <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41339342
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1038/s41523-025-00851-7
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 135
    Titles:
      – TitleFull: CDK2 inhibition enhances CDK4/6 inhibitor antitumor activity in comprehensive breast cancer PDX model screen.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: House NC
      – PersonEntity:
          Name:
            NameFull: Chen MM
      – PersonEntity:
          Name:
            NameFull: Khazaei S
      – PersonEntity:
          Name:
            NameFull: Brown V
      – PersonEntity:
          Name:
            NameFull: Ramsden P
      – PersonEntity:
          Name:
            NameFull: Peng DH
      – PersonEntity:
          Name:
            NameFull: Moore S
      – PersonEntity:
          Name:
            NameFull: Yuan L
      – PersonEntity:
          Name:
            NameFull: Wu R
      – PersonEntity:
          Name:
            NameFull: Wang F
      – PersonEntity:
          Name:
            NameFull: Luo L
      – PersonEntity:
          Name:
            NameFull: Feng N
      – PersonEntity:
          Name:
            NameFull: Bristow CA
      – PersonEntity:
          Name:
            NameFull: Yap TA
      – PersonEntity:
          Name:
            NameFull: Keyomarsi K
      – PersonEntity:
          Name:
            NameFull: Marszalek JR
      – PersonEntity:
          Name:
            NameFull: Ribich S
      – PersonEntity:
          Name:
            NameFull: Rinne ML
      – PersonEntity:
          Name:
            NameFull: Muthuswamy LB
      – PersonEntity:
          Name:
            NameFull: Faia KL
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 03
              M: 12
              Text: 2025 Dec 03
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-print
              Value: 2374-4677
          Numbering:
            – Type: volume
              Value: 11
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: NPJ breast cancer
              Type: main
ResultId 1